Von der Kombinationstherapie und Zielwerterreichung zu Tirzepatid bei HFpEF

Quellen:

 

Ray KK et al.. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. 2024 Nov 11;31(15):1792-1803. doi: 10.1093/eurjpc/zwae199. PMID: 38861400.

 

Packer M et al.. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2410027. Epub ahead of print. PMID: 39555826.

Kategorien: Allgemein